Tags

Type your tag names separated by a space and hit enter

The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women.
Eur J Contracept Reprod Health Care. 1996 Dec; 1(4):325-9.EJ

Abstract

OBJECTIVE

In women who use oral contraceptives with low estrogen doses, a quiescent endometrium is frequently produced. Further reduction of the estrogen dose would not be expected to alter this effect. In this open-label study, the effects on the endometrium of a monophasic oral contraceptive containing 75 micrograms gestodene and 20 micrograms ethinylestradiol were assessed.

METHOD

Biopsies were performed on 25 women on therapy. The biopsies were performed during the late luteal phase (last 7 days) in the pretreatment cycle and during days 15-21 in cycle 6 for 13 subjects (Group A) and during days 15-21 in cycle 3 and during the late luteal phase (last 7 days) in the post-treatment cycle for 12 subjects (Group B).

RESULTS

All subjects completed six cycles of treatment. Nine of 13 subjects pretreatment and nine of 12 subjects at cycle 3 were characterized by the pathologist as having a secretory endometrium. Four of 13 subjects at cycle 6 and ten of 11 subjects post-treatment also demonstrated a secretory endometrium. Pre-decidual changes were seen in one, two, two and zero subjects at pretreatment, after three cycles, six cycles, and post-treatment, respectively. Six subjects had an atrophic endometrium at cycle 6.

CONCLUSIONS

With monophasic gestodene/ethinylestradiol 75 micrograms/20 micrograms, a secretory or inactive endometrium was present in most subjects. Thus, the effects on the endometrium of this oral contraceptive containing a reduced estrogen dose are consistent with those produced by other low-estrogen-dose combination oral contraceptives.

Authors+Show Affiliations

Academisch Ziekenhuis Nijmegen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

9678115

Citation

Coenen, C M., et al. "The Effects of a Low-dose Gestodene-containing Oral Contraceptive On Endometrial Histology in Healthy Women." The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, vol. 1, no. 4, 1996, pp. 325-9.
Coenen CM, Hollanders JM, Rolland R, et al. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care. 1996;1(4):325-9.
Coenen, C. M., Hollanders, J. M., Rolland, R., Spielmann, D., & Bulten, J. (1996). The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, 1(4), 325-9.
Coenen CM, et al. The Effects of a Low-dose Gestodene-containing Oral Contraceptive On Endometrial Histology in Healthy Women. Eur J Contracept Reprod Health Care. 1996;1(4):325-9. PubMed PMID: 9678115.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. AU - Coenen,C M, AU - Hollanders,J M, AU - Rolland,R, AU - Spielmann,D, AU - Bulten,J, PY - 1996/12/1/pubmed PY - 1998/7/25/medline PY - 1996/12/1/entrez SP - 325 EP - 9 JF - The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception JO - Eur J Contracept Reprod Health Care VL - 1 IS - 4 N2 - OBJECTIVE: In women who use oral contraceptives with low estrogen doses, a quiescent endometrium is frequently produced. Further reduction of the estrogen dose would not be expected to alter this effect. In this open-label study, the effects on the endometrium of a monophasic oral contraceptive containing 75 micrograms gestodene and 20 micrograms ethinylestradiol were assessed. METHOD: Biopsies were performed on 25 women on therapy. The biopsies were performed during the late luteal phase (last 7 days) in the pretreatment cycle and during days 15-21 in cycle 6 for 13 subjects (Group A) and during days 15-21 in cycle 3 and during the late luteal phase (last 7 days) in the post-treatment cycle for 12 subjects (Group B). RESULTS: All subjects completed six cycles of treatment. Nine of 13 subjects pretreatment and nine of 12 subjects at cycle 3 were characterized by the pathologist as having a secretory endometrium. Four of 13 subjects at cycle 6 and ten of 11 subjects post-treatment also demonstrated a secretory endometrium. Pre-decidual changes were seen in one, two, two and zero subjects at pretreatment, after three cycles, six cycles, and post-treatment, respectively. Six subjects had an atrophic endometrium at cycle 6. CONCLUSIONS: With monophasic gestodene/ethinylestradiol 75 micrograms/20 micrograms, a secretory or inactive endometrium was present in most subjects. Thus, the effects on the endometrium of this oral contraceptive containing a reduced estrogen dose are consistent with those produced by other low-estrogen-dose combination oral contraceptives. SN - 1362-5187 UR - https://www.unboundmedicine.com/medline/citation/9678115/The_effects_of_a_low_dose_gestodene_containing_oral_contraceptive_on_endometrial_histology_in_healthy_women_ L2 - http://www.tandfonline.com/doi/full/10.3109/13625189609150678 DB - PRIME DP - Unbound Medicine ER -